P2D Bioscience (P2D) is a specialty pharmaceutical
company focused on developing innovative drugs that fulfill unmet medical needs in the treatment of central nervous system
(CNS) and inflammatory disorders, and cancer.
At P2D, our experienced drug development team utilizes
our in-depth understanding of the clinical treatment of these disorders to efficiently build a product portfolio of therapeutics
with an improved likelihood for clinical success. Our goal is to advance a product candidate through preclinical development
and clinical proof-of-concept by producing powerful and compelling clinical data and then seeking partners to complete the
clinical development and commercialization process.
P2D currently has a pipeline of five drug candidates to treat
attention deficit/hyperactivity disorder (ADHD), Chronic Obstructive Pulmonary Disease (COPD) and Alzheimer’s disease